Outcome | Treatment effect (θ) | 95% CI for θ | U-test (p-value) | τ 2 | NNT/NNH (95% CI) |
---|---|---|---|---|---|
Efficacy | |||||
Reduction in 24-hour pain intensity | -1.437 | (-2.211; -0.663) | <0.001 | 0.109 | * |
Tolerability | |||||
Premature study discontinuation due to: | |||||
- Lack of efficacy | -1.066 | (-2.786; 0.653) | 0.224 | 0 | |
- Adverse events | 0.241 | (-0.786; 1.267) | 0.646 | 0 | 63 (30; ∞) |
- Other | -0.036 | (-1.162; 1.090) | 0.950 | 0 | |
Diarrhoea | 0.393 | (-0.555; 1.341) | 0.416 | 0 | |
Dizziness | 1.833 | (0.834; 2.833) | <0.001 | 0 | |
Headache | 1.146 | (-0.018; 2.310) | 0.054 | 0 | |
Nausea | 0.595 | (-0.532; 1.722) | 0.301 | 0 | |
Somnolence | 1.582 | (0.643; 2.520) | 0.001 | 0 |